<SEC-DOCUMENT>0000899140-21-000501.txt : 20210520
<SEC-HEADER>0000899140-21-000501.hdr.sgml : 20210520
<ACCEPTANCE-DATETIME>20210520171251
ACCESSION NUMBER:		0000899140-21-000501
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20210520
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210520
DATE AS OF CHANGE:		20210520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innoviva, Inc.
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943265960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30319
		FILM NUMBER:		21945401

	BUSINESS ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		6502389600

	MAIL ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	THERAVANCE INC
		DATE OF NAME CHANGE:	20020207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>i052021a.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: asdf
         Document created using EDGARfilings PROfile 7.4.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <br>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.6pt; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 93.4pt; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 93.4pt; margin-top: 0.65pt; font-size: 8pt; font-weight: bold;">Washington, DC 20549</div>
    <div style="text-align: center; margin-right: 93.6pt; margin-left: 93.4pt; margin-top: 2.85pt; margin-bottom: 5.6pt; font-size: 14pt; font-weight: bold;"> <font style="font-size: 10pt;">_______________________</font><br>
      <div><font style="font-weight: normal; font-size: 6pt;">&#160;</font><br>
      </div>
    </div>
    <div style="text-align: center; margin-right: 93.6pt; margin-left: 93.4pt; margin-top: 2.85pt; margin-bottom: 5.6pt; font-size: 14pt; font-weight: bold;">FORM 8-K</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.9pt; margin-top: 4.8pt; font-weight: bold;">_______________________<br>
      <div><br>
      </div>
      CURRENT REPORT</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.75pt; margin-top: 1.1pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
    <div style="text-align: center; margin-right: 93.55pt; margin-left: 93.4pt; margin-top: 1.1pt;">Date of Report (Date of earliest event reported): May 20<font style="font-weight: bold;">, <font style="font-weight: normal;">2021</font></font></div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.7pt; margin-top: 2.85pt; font-size: 14pt; font-weight: bold;"> <font style="font-size: 10pt;">_______________________</font></div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.7pt; margin-top: 2.85pt; font-size: 14pt; font-weight: bold;"><font style="font-weight: normal; font-size: 6pt;">&#160; </font><br>
    </div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.7pt; margin-top: 2.85pt; font-size: 14pt; font-weight: bold;">INNOVIVA, INC.</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.7pt; margin-top: 2.85pt; font-size: 14pt; font-weight: bold;"><font style="font-size: 10pt;">_______________________</font> </div>
    <div style="text-align: center; margin-right: 93.6pt; margin-left: 93.6pt; margin-top: 6pt; margin-bottom: 6pt;">(Exact Name of Registrant as Specified in its Charter)</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z547a7eb3a14346efb0336ab8d854f359">

        <tr>
          <td style="width: 33.34%; vertical-align: top;">
            <div style="text-align: center; font-size: 8pt; font-weight: bold;">Delaware<br>
              (State or Other Jurisdiction of Incorporation)</div>
          </td>
          <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; font-size: 8pt; font-weight: bold;">000-30319<br>
              (Commission&#160; File Number)<br>
              1350 Old Bayshore Highway, Suite 400<br>
              Burlingame, California 94010<br>
              (650) 238-9600</div>
          </td>
          <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; font-size: 8pt; font-weight: bold;">94-3265960<br>
              (I.R.S. Employer Identification Number)</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; margin-top: 6pt;">(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)<br>
      (Former name or former address, if changed since last report)</div>
    <div style="text-align: center; margin-top: 6pt; margin-bottom: 6pt;">_______________________</div>
    <div style="text-align: justify; margin-top: 3.7pt; margin-bottom: 6pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
      General Instruction A.2. below):</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-bottom: 6pt; margin-top: 6pt;" class="DSPFListTable" id="ze0f934fbb1a14051938a0f61590d63a4">

        <tr>
          <td style="width: 27.35pt; vertical-align: top; align: right;">&#9744;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-bottom: 6pt; margin-top: 0.85pt;" class="DSPFListTable" id="zddfa9a97483b4a0c9ae3a6acb7062bca">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">&#9744;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-bottom: 6pt; margin-top: 0.85pt;" class="DSPFListTable" id="z90182624a4d744ce9b4bf843ae87c1ac">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">&#9744;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-bottom: 6pt; margin-top: 0.85pt;" class="DSPFListTable" id="zb1a6c4aa0c564ef784e15dbef638f3d1">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">&#9744;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; margin-top: 0.85pt; margin-bottom: 6pt;">Securities registered pursuant to Section 12(b) of the Act:</div>
    <div style="margin-top: 0.85pt; margin-bottom: 6pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="z2015c7705a7e481f934b92ff5c4f31e7">

        <tr>
          <td style="width: 37.6%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Title of each class</div>
          </td>
          <td style="width: 24.73%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Trading Symbol(s)</div>
          </td>
          <td style="width: 37.67%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Name of each exchange on which registered</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.6%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Common Stock, par value $0.01 per share</div>
          </td>
          <td style="width: 24.73%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">INVA</div>
          </td>
          <td style="width: 37.67%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">The NASDAQ Global Select Market</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; margin-top: 6pt; margin-bottom: 6pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(&#167;230.405 of this chapter) or Rule 12b-2 of the
      Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company &#9744;</div>
    <div style="text-align: justify; margin-top: 6pt; margin-bottom: 6pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
      accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>
    <div style="text-align: justify; margin-top: 6pt; margin-bottom: 6pt;"> <br>
    </div>
    <div style="margin-bottom: 6pt;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="margin-bottom: 12pt; font-size: 12pt; font-weight: bold;">Item 1.01. Entry into a Material Definitive Agreement.</div>
    <div style="text-align: justify; text-indent: 72pt; margin-right: 16.25pt; margin-bottom: 12pt; font-size: 12pt;">On May 20, 2021, Innoviva, Inc. (&#8220;<u>Innoviva</u>&#8221;) entered into a share repurchase agreement (the &#8220;<u>Share Repurchase Agreement</u>&#8221;) to
      purchase 32,005,260 shares of its common stock, par value $0.01 per share, from Glaxo Group Limited (&#8220;<u>GSK</u>&#8221;) (the &#8220;<u>Transaction</u>&#8221;), representing all of the shares of common stock or other capital interests of Innoviva owned by GSK or its
      affiliates. The purchase price under the Share Repurchase Agreement is $12.25 per share, resulting in a total consideration of $392,064,435. The closing of the purchase under the Share Repurchase Agreement is expected to occur on or before May 25,
      2021.</div>
    <div style="text-align: justify; text-indent: 72pt; margin-right: 16.25pt; margin-bottom: 12pt; font-size: 12pt;">In order to provide proceeds to Innoviva to fund a portion of the Transaction, Innoviva Strategic Partners LLC (&#8220;<u>Strategic Partners</u>&#8221;),

      a wholly owned subsidiary of Innoviva, will receive a distribution of $110,000,000 from ISP Fund LP (the &#8220;<u>Partnership</u>&#8221;), in accordance with that certain Letter Agreement, dated May 20, 2021, by and among Strategic Partners, the Partnership and
      Sarissa Capital Fund GP LP (the &#8220;<u>Letter Agreement</u>&#8221;). Under the terms of the Letter Agreement, Strategic Partners has committed to make additional capital contributions to the Partnership in an amount equal to the distribution.&#160; The Letter
      Agreement, and the transactions contemplated thereby, were approved by the audit committee of Innoviva&#8217;s Board of Directors.</div>
    <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-size: 12pt;">The foregoing is a summary description of certain terms of the Share Repurchase Agreement and the Letter Agreement and does not purport to be complete, and is
      qualified in its entirety by reference to the full text of the Share Repurchase Agreement and the Letter Agreement, which are attached hereto as Exhibit 10.1 and 10.2 (respectively) and are incorporated herein by reference.</div>
    <div style="text-align: justify; margin-right: 14pt; margin-bottom: 12pt; font-size: 12pt; font-weight: bold;">Item 8.01. Other Events.</div>
    <div style="text-align: justify; text-indent: 72pt; margin-right: 16.25pt; margin-bottom: 12pt; font-size: 12pt;">On May 20, 2021, Innoviva issued a press release announcing the execution of the Share Repurchase Agreement.&#160; A copy of the press release
      is attached hereto as Exhibit 99.1.</div>
    <div style="margin-top: 0.1pt; margin-bottom: 12pt; font-size: 12pt; font-weight: bold;">Item 9.01. Financial Statements and Exhibits.</div>
    <div style="margin-top: 0.85pt; margin-bottom: 12pt; font-size: 12pt; font-weight: bold;">(d) Exhibits</div>
    <div style="margin-top: 0.85pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">10.1</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 39.5pt" id="TRGRRTFtoHTMLTab">&#160;</font><font style="font-size: 12pt;">Share
        Repurchase Agreement, dated as of May 20, 2021, by and between Innoviva, Inc. and Glaxo Group Limited.</font></div>
    <div style="margin-top: 0.85pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">10.2</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 39.5pt" id="TRGRRTFtoHTMLTab">&#160;</font><font style="font-size: 12pt;">Letter
        Agreement, dated as of May 20, 2021, by and among Innoviva Strategic Partners LLC, ISP Fund LP and Sarissa Capital Fund GP LP.</font></div>
    <div style="margin-bottom: 12pt;"><font style="font-size: 12pt;">99.1</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt" id="TRGRRTFtoHTMLTab">&#160;</font><font style="font-size: 12pt;"> Press Release, dated May 20,
        2021.</font></div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="margin: 0px 0px 12pt; text-align: center;">SIGNATURE</div>
    <div style="text-indent: 72pt; margin-right: 13.7pt; margin-bottom: 12pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
      hereunto duly authorized.</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbd1028a6fea648d9a344a33249589c5b">

        <tr>
          <td style="width: 47.51%; vertical-align: top;">
            <div style="margin-right: 13.95pt;">Date: May 20, 2021</div>
          </td>
          <td style="width: 52.49%; vertical-align: top;">
            <div style="text-indent: -19.2pt; margin-left: 19.2pt; font-weight: bold;">INNOVIVA, INC.</div>
            <div>&#160;</div>
            <div style="text-indent: -19.2pt; margin-left: 19.2pt; font-weight: bold;">By:&#160; <u>/s/ Pavel Raifeld&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 12pt" id="TRGRRTFtoHTMLTab">&#160; </font></u><br>
              Pavel Raifeld<br>
              Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="margin-top: 0.9pt; margin-bottom: 12pt;"><br>
    </div>
    <div style="margin-top: 0.9pt; margin-bottom: 12pt;"><br>
    </div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>i052021b.htm
<DESCRIPTION>SHARE REPURCHASE AGREEMENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: asdf
         Document created using EDGARfilings PROfile 7.4.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-size: 12pt;">Exhibit 10.1</font><br>
  </div>
  <div style="text-align: right;"><br>
    <div style="text-align: center; margin-bottom: 12pt; font-size: 12pt; font-weight: bold;">SHARE REPURCHASE AGREEMENT</div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-size: 12pt;">THIS SHARE REPURCHASE AGREEMENT (this "<u>Agreement</u>") is made and entered into as of May 20, 2021, by and between Innoviva, Inc., a Delaware corporation ("<u>Company</u>"),

      and Glaxo Group Limited, a private company limited by shares registered under the laws of England and Wales ("<u>Seller</u>").</div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">1.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Purchase and Sale of Shares</u>.</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(a)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Purchase and Sale</u>. Upon the terms set forth in this Agreement, effective as of the Closing, the Company hereby purchases from the Seller, and the Seller hereby sells to the Company, 32,005,260<font style="font-weight: bold;">&#160;</font>shares


        of common stock of the Company, par value $0.01 per share, owned by Seller (the "<u>Shares</u>"), representing all of the shares of common stock or other capital interests of the Company owned beneficially or of record by GlaxoSmithKline plc, the
        ultimate parent company of Seller (&#8220;<u>GSK</u>&#8221;), or its controlled affiliates (excluding any securities held by any employee benefit plan or similar plan or entity), at a price per Share of $12.25, representing aggregate consideration for all such
        Shares of $392,064,435 (the &#8220;<u>Closing Consideration</u>&#8221;).</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">2.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Settlement</u>.&#160; The closing of the purchase by the Company and sale by the Seller of the Shares (the &#8220;<u>Closing</u>&#8221;) shall be held on May 25, 2021, or on such other date and time as the Company and Seller agree (the "<u>Closing Date</u>").

        On the Closing Date, (i) the Company shall pay the Closing Consideration for all of the Shares purchased and sold hereunder by wire transfer of immediately available funds to such account as the Seller shall have specified in writing and (ii) the
        Company and the Seller shall cause the Shares to be transferred to the Company's account at the Company's transfer agent and the Seller shall deliver appropriate stock transfer powers representing the Shares in customary form.&#160; On or promptly after
        the Closing Date, the Seller shall deliver the stock certificates representing the Shares&#160; or customary lost stock affidavits in lieu thereof.&#160; The obligations of the parties to consummate the Closing shall be conditioned only on there being, as of
        the Closing Date, no injunctions, orders or other restraints issued by a governmental authority with competent jurisdiction restraining or prohibiting the consummation of the Closing and the delivery by the Seller of the Shares free and clear of
        any liens, encumbrances, or charges, of any kind (other than any lien, encumbrance or charge arising as a result of the Company&#8217;s purchase or ownership of any such Shares or which arise under applicable federal and state securities laws).</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">3.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Representations and Warranties of Seller</u>.&#160; The Seller represents and warrants to the Company as of the date hereof and as of the Closing Date as follows:</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(a)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Seller owns all of the Shares. No person or entity has asserted in writing any claim or commenced or threatened any litigation concerning the Seller's title to the Shares. Upon delivery of the Shares, the Seller will convey to Company
        valid title to the Seller's Shares, free and clear of any liens, encumbrances, or charges, of any kind (other than any lien, encumbrance or charge arising as a result of the Company&#8217;s purchase or ownership of any such Shares or which arise under
        applicable federal and state securities laws);</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(b)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">Other than as set forth in this Agreement and as is being sold to the Company hereunder, GSK and its controlled affiliates (excluding any securities held by any employee benefit plan or similar plan or entity) do not own, beneficially or of
        record, any shares of capital stock or other equity interests in the Company;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(c)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Seller is a private company limited by shares registered under the laws of England and Wales and is duly organized and validly existing;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(d)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Seller has the corporate power and authority to enter into this Agreement and the transactions contemplated hereby have been duly authorized by all necessary corporate action of Company;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(e)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">This Agreement constitutes a legal, valid and binding obligation of the Seller, enforceable against the Seller in accordance with its terms, except as enforceability may be affected by bankruptcy, insolvency, moratorium or similar laws or by
        legal or equitable principles related to or limiting creditors' rights generally;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(f)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The execution, delivery and performance of this Agreement by the Seller and the consummation of the transactions contemplated hereby will not result in a breach or violation by the Seller of, or constitute a default by the Seller under any
        of Seller&#8217;s governing documents or any judgment, decree, order, governmental permit, license, agreement, indenture, instrument, statute, rule or regulation to which the Seller is a party or by which the Seller is bound, in each case, other than any
        breach, violation or default that would not materially impair the ability of the Seller to perform its obligations under this Agreement or to consummate the transactions contemplated hereby, and no authorization, approval or consent, except such as
        have been obtained, is required in connection with the execution, delivery and performance by the Seller of this Agreement or the consummation of the transactions contemplated hereby;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(g)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Seller has (i) reviewed the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Securities and Exchange Commission (the "<u>SEC</u>") on February 25, 2021, the Company's Quarterly Reports on
        Form 10-Q for the quarterly period ended March 31, 2021, filed with the SEC on April 28, 2021, the Company's Current Reports on Form 8-K filed with the SEC after December 31, 2020, and the other publicly available filings made by Company with the
        SEC, information and reports furnished by Company, other publicly available information regarding the Company, and such other information that it and its advisers deem necessary and sufficient to make its decision to enter into this Agreement, (ii)
        made Seller's own investigations of the Company, its businesses, personnel, operations and prospects, (iii) had an opportunity to discuss the Company's business, management and financial affairs with officers of the Company and (iv) conducted and
        completed its own independent due diligence with respect to the transactions contemplated by this Agreement;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(h)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">Seller (i) has independently made its own analysis and decision to enter into the transactions contemplated by this Agreement, (ii) is relying exclusively on its own investment analysis and due diligence (including such professional advice
        as it deems appropriate) and the representations and warranties by the Company set forth herein with respect to the transactions contemplated by this Agreement, the Shares and the business, condition (financial and otherwise), management,
        operations, properties and prospects of the Company and (iii) hereby waives any claims against the Company with respect to such investigation, analysis and investment decision;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(i)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Seller acknowledges that the Company may be privy to material non-public information regarding the Company (collectively, the &#8220;<u>Non-Public Information</u>&#8221;), which may be material to a reasonable investor, such as the Seller, when
        making investment disposition decisions, including the decision to enter into the Agreement, and the Seller&#8217;s decision to enter into the Agreement is being made with full recognition and acknowledgment that the Company may be privy to the
        Non-Public Information, irrespective of whether such Non-Public Information has been provided to the Seller. The Seller hereby waives any claim, or potential claim, it has or may have against the Company relating to the Company&#8217;s possession of
        Non-Public Information in connection with the matters contemplated by this Agreement and the Company shall not have any liability to the Seller, and the Seller to the fullest extent of the law waives and releases any claims, whether known or
        unknown, that it might have against the Company, whether under applicable securities laws or otherwise, with respect to the&#160; nondisclosure of the Non-Public Information in connection with the purchase of the Shares and the transactions contemplated
        by this Agreement;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(j)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Seller acknowledges and agrees that the Company is relying on Seller's representations, warranties and agreements herein in proceeding with this Agreement and the transactions contemplated hereby and the Seller agrees to such reliance.
        Without such representations, warranties and agreements, the Company would not enter into this Agreement and the transactions contemplated hereby; and</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(k)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Seller acknowledges that it has not relied upon any express or implied representations or warranties of any nature made by or on behalf of the Company or its subsidiaries, whether or not any such representations, warranties or statements
        were made in writing or orally, except as expressly set forth for the benefit of the Seller in this Agreement.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">4.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Representations and Warranties of Company</u>.&#160; The Company represents and warrants to the Seller as of the date hereof and as of the Closing Date as follows:</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(a)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Company is a corporation duly organized, validly existing, and in good standing under the laws of the State of Delaware;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(b)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">This Agreement constitutes a legal, valid and binding obligation of Company, enforceable against Company in accordance with its terms, except as enforceability may be affected by bankruptcy, insolvency, fraudulent conveyance, moratorium or
        similar laws or by legal or equitable principles related to or limiting creditors' rights generally;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(c)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Company has the corporate power and authority to enter into this Agreement and the transactions contemplated hereby have been duly authorized by all necessary corporate action of Company;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(d)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The execution, delivery and performance of this Agreement by the Company and the consummation of the transactions contemplated hereby will not result in a breach or violation by Company of, or constitute a default by the Company under any of
        its governing documents or any judgment, decree, order, governmental permit, license, agreement, indenture, instrument, statute, rule or regulation to which it or any of its subsidiaries is a party or by which it or any of its subsidiaries is bound
        or to which any of its or any of its subsidiaries&#8217; properties or assets is subject, in each case, other than any breach, violation or default that would not materially impair the ability of the Company to perform its obligations under this
        Agreement or to consummate the transactions contemplated hereby, and no authorization, approval or consent, except to the extent obtained, is required in connection with the execution, delivery and performance by the Company of this Agreement or
        the consummation of the transactions contemplated hereby;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(e)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Company will have as of the Closing Date legally available funds sufficient to consummate the transactions contemplated by this Agreement. After giving effect to the transactions contemplated hereby, the Company will have adequate
        surplus and the transactions contemplated hereby will be in compliance with Section 160 of the Delaware General Corporation Law;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(f)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">Both immediately prior to and after giving effect to the transactions contemplated hereby, the Company shall be Solvent (as defined below).&#160; For purposes of this Agreement, the term &#8220;<u>Solvent</u>&#8221; means that, as of the applicable time of
        determination, the Company and its subsidiaries, taken as a whole, (A) are able to pay their respective debts as they become due; (B) own property which has a fair value greater than the amounts required to pay their respective debts (including a
        reasonable estimate of the amount of all contingent liabilities); and (C) have adequate capital to carry on their respective businesses.&#160; No transfer of property is being made and no obligation is being incurred in connection with the transactions
        contemplated by this Agreement with the intent to hinder, delay or defraud either present or future creditors of the Company or its subsidiaries;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(g)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Company (i) has independently made its own analysis and decision to enter into the transactions contemplated by this Agreement, (ii) is relying exclusively on its own investment analysis and due diligence (including such professional
        advice as it deems appropriate) and the representations and warranties of the Seller set forth herein with respect to the transactions contemplated by this Agreement, the Shares and the business, condition (financial and otherwise), management,
        operations, properties and prospects of the Company and (iii) hereby waives any claims against the Seller with respect to such investigation, analysis and investment decision;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(h)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Company acknowledges that the Seller may be privy to material non-public information regarding matters affecting the Company (collectively, the &#8220;<u>Seller Non-Public Information</u>&#8221;), which may be material to the Company when making
        investment decisions, including the decision to enter into the Agreement, and the Company&#8217;s decision to enter into the Agreement is being made with full recognition and acknowledgment that the Seller may be privy to Seller Non-Public Information,
        irrespective of whether such Seller Non-Public Information has been provided to the Company. The Company hereby waives any claim, or potential claim, it has or may have against the Seller relating to the Seller&#8217;s possession of Seller Non-Public
        Information in connection with the matters contemplated by this Agreement and the Seller shall not have any liability to the Company, and the Company to the fullest extent of the law waives and releases any claims, whether known or unknown, that it
        might have against the Seller, whether under applicable securities laws or otherwise, with respect to the nondisclosure of the Seller Non-Public Information in connection with the sale of the Shares and the transactions contemplated by this
        Agreement;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(i)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Company has reviewed such information that it and its advisers deem necessary and sufficient to make its decision to enter into this Agreement, had an opportunity to discuss the Seller Non-Public Information with the Seller and conducted
        and completed its own independent due diligence with respect to the transactions contemplated by this Agreement;</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(j)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Company acknowledges and agrees that the Seller is relying on the Company&#8217;s representations, warranties and agreements herein in proceeding with this Agreement and the transactions contemplated hereby and the Company agrees to such
        reliance. Without such representations, warranties and agreements, the Seller would not enter into this Agreement and the transactions contemplated hereby; and</font></div>
    <div style="text-align: left; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">(k)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;">The Company acknowledges that it has not relied upon any express or implied representations or warranties of any nature made by or on behalf of the Seller or its affiliates, whether or not any such representations, warranties or statements
        were made in writing or orally, except as expressly set forth for the benefit of the Company in this Agreement.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">5.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Survival of Representations, Warranties and Covenants</u>.&#160; All representations, warranties and covenants contained herein shall survive the execution of this Agreement and the consummation of the transactions contemplated hereby.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">6.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Successors and Assigns</u>.&#160; This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, representatives, successors and assigns.&#160; The Agreement may not be assigned by either party
        without the prior written consent of the other party.&#160; Any assignment purported to be made in violation of the foregoing shall be null and void.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">7.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Severability</u>.&#160; In the event that any portion of this Agreement may be held to be invalid or unenforceable for any reason, it is hereby agreed that such invalidity or unenforceability shall not affect the other portions of this
        Agreement and that the remaining covenants, terms and conditions or portions hereof shall remain in full force and effect, and any court of competent jurisdiction may so modify the objectionable provision as to make it valid, reasonable and
        enforceable.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">8.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Entire Agreement</u>.&#160; This Agreement contains the complete agreement among the parties hereto with respect to the transactions contemplated hereby and supersedes all prior agreements and understandings among the parties hereto with
        respect to such transactions.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">9.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Governing Law</u>.&#160; This Agreement and any proceeding, dispute or controversy (a &#8220;<u>Proceeding</u>&#8221;) or other matter relating hereto or thereto (or the negotiation hereof) shall be construed and enforced in accordance with the laws of
        the State of Delaware without giving effect to any conflicts of law rules or provisions that would compel the application of the substantive laws of another jurisdiction.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">10.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Venue</u>. All Proceedings arising out of or relating to this Agreement (or the negotiation hereof) shall be heard and determined exclusively in the Delaware Court of Chancery and the appellate courts therefrom or, solely to the extent
        such courts lack jurisdiction, any federal court sitting in the State of Delaware and any appellate courts therefrom.&#160; Consistent with the preceding sentence, the parties hereto hereby (a) submit to the exclusive jurisdiction of such courts for the
        purpose of any such Proceeding brought by any party hereto and (b) irrevocably waive, and agree not to assert by way of motion, defense, or otherwise, in any such Proceeding, any claim that it is not subject personally to the jurisdiction of the
        above named courts, that its property is exempt or immune from attachment or execution, that the Proceeding is brought in an inconvenient forum, that the venue of the Proceeding is improper, or that this Agreement or the transactions contemplated
        by this Agreement may not be enforced in or by any of the above named courts.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">11.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Specific Performance</u>. The parties hereby agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any provision of this Agreement (including failing to
        take such actions as are required of any party hereunder to consummate the transactions contemplated hereby) is not performed in accordance with its specific terms or is otherwise breached.&#160; Accordingly, the parties agree that each party shall be
        entitled to an injunction or injunctions, or any other appropriate form of specific performance or equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof and thereof in any court of
        competent jurisdiction in accordance with <u>Section 10</u>, this being in addition to any other remedy to which they are entitled under the terms of this Agreement, at law, in equity or otherwise, and each party hereby waives any requirement for
        the securing or posting of any bond or other collateral in connection with such remedy or any right to object to any such remedy.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">12.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Waiver of Jury Trial</u>.&#160; Each of the parties hereto hereby waives to the fullest extent permitted by applicable law any right it may have to a trial by jury with respect to any litigation directly or indirectly arising out of, under or
        in connection with this Agreement or the transactions contemplated by this Agreement.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">13.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Further Assurances</u>.&#160; Each of the parties hereto shall take, or cause to be taken, all appropriate action, to do or cause to be done all things necessary, proper or advisable under applicable law, and to execute and deliver such
        documents and other papers, as may be required to carry out the provisions of this Agreement and to consummate and make effective the transaction contemplated by this Agreement.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">14.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Public Announcements</u>.&#160; The parties agree that (i) the initial press release by the Seller, the initial press release by the Company, and the SEC filing on Form 8-K by the Company, each disclosing the execution and delivery of this
        Agreement and the transactions contemplated hereby and the SEC filing on Form 8-K by the Company disclosing the results of the Company&#8217;s annual meeting shall be in the forms attached hereto as <u>Exhibits A-D</u> (the &#8220;<u>Agreed Disclosures</u>&#8221;).&#160;

        Each of the parties agrees that, other than the Agreed Disclosures or as permitted by the immediately succeeding sentence, and except as may be required by law, rule, regulation or the requirements of any self-regulatory organization or stock
        exchange listing requirements (in which case the party required to make the filing, disclosure, communication, release or announcement shall allow the other party reasonable time to comment thereon in advance of such statement, release, filing,
        disclosure, communication or announcement and will consider in good faith any comments provided by such party), each of the parties hereto will not make any public statement, press release or other public filing, disclosure, communication, release,
        or announcement with respect to this Agreement and any of the transactions contemplated by this Agreement, including the circumstances or discussions (to the extent related to the Seller&#8217;s relationship with the Company as a stockholder of the
        Company and not, for clarity, in connection with the Commercial Agreements (as defined below)) in the twelve months leading to the negotiation and execution of this Agreement (or substantially the same circumstances or discussions prior thereto);
        provided, that nothing herein shall limit or prevent a party from making any statements, press releases or other filings, disclosures, communications, releases or announcements to the extent reasonably related to such party exercising or enforcing
        any of its rights under this Agreement.&#160; Notwithstanding the foregoing, each of the parties shall be entitled to make public statements or disclosures that are substantially consistent with the Agreed Disclosures; provided, that Seller shall
        provide the Company with a reasonable time to review and comment on the amendment to Schedule 13D of the Seller (or its affiliates).</font></div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">15.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Fees and Expenses</u>.&#160; All costs and expenses incurred in connection with this Agreement and the transaction contemplated by this Agreement shall be the responsibility of and shall be paid by the party incurring such fees or expenses,
        whether or not the transaction contemplated by this Agreement is consummated.</font></div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">16.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Entire Agreement</u>.&#160; This Agreement contains the entire agreement and understanding between the parties with respect to the subject matter hereof and supersede all prior agreements and understandings relating to such subject matter.&#160;
        For the avoidance of doubt, nothing herein shall limit or amend the rights or obligations of any party or any of their affiliates (including the right to receive royalties) under that certain Collaboration Agreement, dated as of November 14, 2002
        or that certain Strategic Alliance Agreement, dated as of March 30, 2004, each as amended from time to time, and any related agreements or instruments (collectively, the &#8220;<u>Commercial Agreements</u>&#8221;).</font></div>
    <u> </u>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">17.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Amendments; Waiver</u>.&#160; No amendment to this Agreement shall be effective unless it shall be in writing and signed by all parties.&#160; No waiver of any term, provision or condition of this Agreement will be effective unless memorialized in
        writing and signed by the party against whom such waiver is to be enforced; and no waiver of any breach of this Agreement will be implied from any forbearance or failure of a party to take action thereon.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">18.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Pre-Closing Rights</u>.&#160; Nothing contained in this Agreement shall in anyway alter, limit or impair or be interpreted to alter, limit or impair the rights, privileges or obligations of the Seller with respect to the Seller&#8217;s ownership of
        the Shares prior to the Closing, including the right of the Seller to, prior to the Closing, receive any dividends payable on the Shares prior to the Closing or vote the Shares with respect to any matters submitted for a stockholder vote prior to
        the Closing.</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt;">19.</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt;"><u>Counterparts</u>.&#160; This Agreement may be executed by facsimile or electronic signature and in two or more counterparts, each of which shall be deemed an original but all of which shall constitute but one instrument.</font></div>
    <div style="text-align: center; margin-bottom: 12pt; font-size: 12pt; font-style: italic;">[Remainder of page intentionally left blank. Signature page follows.]</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-size: 12pt;">IN WITNESS WHEREOF, the parties thereto have executed this Agreement as of the date first above written.</div>
    <div style="text-align: left; margin-left: 216pt; font-size: 12pt;">COMPANY</div>
    <div><br>
    </div>
    <div style="text-align: left; margin-left: 216pt; font-size: 12pt; font-weight: bold;">INNOVIVA, INC.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; margin-left: 216pt; font-size: 12pt;">By:&#160; <u>/s/ Pavel Raifeld&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
      </u></div>
    <div style="text-align: left; margin-left: 238.5pt; font-size: 12pt;">Name: Pavel Raifeld</div>
    <div style="text-align: left; margin-left: 238.5pt; font-size: 12pt;">Title:&#160; Chief Executive Officer</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div style="text-align: left; margin-left: 216pt; font-size: 12pt;">SELLER:</div>
    <div><br>
    </div>
    <div style="text-align: left; margin-left: 216pt; font-size: 12pt; font-weight: bold;">GLAXO GROUP LIMITED</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; margin-left: 216pt; font-size: 12pt;">By: <u>/s/ Peter Hopkins</u>_____________________</div>
    <div style="text-align: left; margin-left: 216pt; font-size: 12pt;">Name: Peter Hopkins<br>
    </div>
    <div style="text-align: left; margin-left: 216pt; font-size: 12pt;">Title: Authorized Signatory by Power of Attorney<br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>i052021c.htm
<DESCRIPTION>LETTER AGREEMENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: asdf
         Document created using EDGARfilings PROfile 7.4.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-size: 12pt;">Exhibit 10.2</font><br>
  </div>
  <div style="text-align: right;"><font style="font-size: 12pt;"> <br>
    </font></div>
  <div><br>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 12pt;"><font style="font-weight: bold;">ISP FUND LP</font><br>
      c/o Sarissa Capital Fund GP LP<br>
      660 Steamboat Road, 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> Floor<br>
      Greenwich, Connecticut&#160; 06830</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">Dated as of May 20, 2021</div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">Innoviva Strategic Partners LLC</div>
    <div style="font-size: 12pt;">1350 Old Bayshore Highway<br>
      Suite 400<br>
      Burlingame, CA 94010</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><font style="font-size: 12pt;">Re:</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt" id="TRGRRTFtoHTMLTab">&#160;</font><font style="font-size: 12pt;">Distribution from ISP Fund LP</font></div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;">Ladies and Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-size: 12pt;">In connection with the investment of Innoviva Strategic Partners LLC (the &#8220;<u>Investor</u>&#8221;) in ISP Fund LP, a Delaware limited partnership (the &#8220;<u>Fund</u>&#8221;),
      Sarissa Capital Fund GP LP (the &#8220;<u>General Partner</u>&#8221;) and the Fund agree with the Investor as follows:</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-size: 12pt;">The Investor is proposing to make a strategic repurchase of shares of the Investor held by Glaxo Group Limited and desires to access capital from its Capital
      Account to fund in part the transaction.&#160; In order to provide the Investor access to the necessary capital for such transaction, the General Partner shall make a distribution to the Investor in the amount up to $110,000,000 as of May 20, 2021, (the
      actual amount distributed , the &#8220;Distribution <u>Amount</u>&#8221;).&#160; The Investor acknowledges and agrees that Performance Allocation shall accrue at the time of distribution as provided in the Partnership Agreement in respect to the Distribution
      Amount.&#160; In consideration of this distribution , the Investor shall make one or more additional Capital Contributions to the Fund in an aggregate amount equal to the Distribution Amount at such time as the Investor has sufficient free and
      unencumbered cash from royalty payments (as determined by the Investor), and in any event prior to March 31 , 2022 (in each case so long as such Capital Contributions shall not result in the Investor or Innoviva Inc. being an &#8220;investment company&#8221;
      within the meaning of the Investment Company Act of 1940 or otherwise have a materially adverse regulatory impact on the Investor or Innoviva).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-size: 12pt;">Each capitalized term used and not otherwise defined in this letter agreement (this &#8220;<u>Letter Agreement</u>&#8221;) shall have the meaning assigned to such term in
      the Fund&#8217;s Amended and Restated Limited Partnership Agreement dated as of December 11, 2020 (the &#8220;<u>Partnership Agreement</u>&#8221;).</div>
    <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;">This Letter Agreement shall be construed in accordance with and governed by the laws of the State of Delaware, without regard to the principles of conflicts of law.&#160; Any claim
      relating to this Letter Agreement shall be brought and maintained only in the Court of Chancery of the State of Delaware, or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the Superior Court of the State of Delaware,
      or, if the Superior Court of the State of Delaware does not have jurisdiction, the United States District Court for the District of Delaware, and each party irrevocably consents (and waives any objection) to the jurisdiction of such courts and to the
      serving of process anywhere in the world.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;">This Letter Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument.&#160;
      Signatures in electronic form shall be as binding on the parties as originals.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;">Each provision of this Letter Agreement shall be considered separable, and if, for any reason, any provision or provisions hereof are determined to be invalid, illegal or
      unenforceable, such invalidity, illegality or unenforceability shall attach only to such provision and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Letter Agreement, and this Letter Agreement
      shall be carried out as if any such illegal, invalid or unenforceable provision were not contained herein.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;">This Letter Agreement shall be binding upon, inure to the benefit of, and may be enforced by, each of the parties to this Letter Agreement and its successors and permitted assigns.&#160;
      Neither this Letter Agreement nor any of the rights, interests or obligations under this Letter Agreement shall be assigned by any party without the prior written consent of the other parties hereto.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 12pt; font-style: italic;">[Signature Pages Follow]</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-indent: -18pt; margin-left: 234pt; font-size: 12pt;">ISP FUND LP</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-indent: -18pt; margin-left: 234pt; font-size: 12pt;">By: <u>/s/ Eric Vincent&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u><br>
      Name: /s/ Eric Vincent<br>
      Title: Authorized Signer<br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-indent: -18pt; margin-left: 234pt; font-size: 12pt;">SARISSA CAPITAL FUND GP LP</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-indent: -18pt; margin-left: 234pt; font-size: 12pt;">By: <u>/s/ Mark DiPaolo&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u><br>
      Name: Mark DiPaolo<br>
      Title: Authorized Signer<br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">Accepted and agreed as of the date first written above:</div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">Innoviva Strategic Partners LLC</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><font style="font-size: 12pt;">By: <u>/s/ Pavel Raifeld&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 216pt" id="TRGRRTFtoHTMLTab"><br>
      </font></div>
    <div style="text-indent: 18.7pt; font-size: 12pt;">Name: Pavel Raifeld<br>
    </div>
    <div style="text-indent: 18.7pt; font-size: 12pt;">Title: CEO<br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>i052021d.htm
<DESCRIPTION>INNOVIVA PRESS RELEASE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: asdf
         Document created using EDGARfilings PROfile 7.4.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center;">
      <div style="text-align: right;"><font style="font-size: 12pt;">Exhibit 99.1</font><br>
      </div>
      <img width="176" height="57" src="image00003.jpg"></div>
    <div style="text-align: center;"><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">Innoviva Announces Strategic Repurchase of GSK&#8217;s Equity Stake</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z91ac8000dac24fbc96d7af5e363bc13e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">
              <div style="margin-left: 18pt;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div>Innoviva to repurchase GSK&#8217;s current 32% stake in the company for $392 million</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">BURLINGAME, Calif., May 20, 2021 &#8211; </font>Innoviva, Inc.
      (NASDAQ: INVA) (&#8220;Innoviva&#8221; and &#8220;the Company&#8221;) today announced the execution of definitive agreement to purchase of GSK&#8217;s equity stake in Innoviva, constituting approximately 32 million shares, or 32% of the outstanding common stock, at $12.25 per
      share, representing a 3% discount to the 5-day volume weighted average price of the Company&#8217;s common stock, for a total purchase price of $392 million.</div>
    <div><br>
    </div>
    <div>Pavel Raifeld, Chief Executive Officer of Innoviva, stated: &#8220;We view the buyback as a compelling and highly accretive transaction demonstrating our ability to
      act strategically and opportunistically at the same time.&#160; We believe that it materially accelerates the delivery of our strategy, while also meaningfully improving our shares&#8217; long-term trading dynamics with an aligned shareholder base.&#160; We remain
      focused on, and strongly positioned for, continued significant value creation for the benefit of all shareholders.&#8221;</div>
    <div><br>
    </div>
    <div>&#8220;GSK was our largest shareholder for many years and remains a key commercial partner.&#160; We are confident in the collaboration products&#8217; excellent commercial
      prospects, especially given strong recent performance in the face of a challenging environment, and look forward to continued work with GSK to address significant unmet medical needs for patients suffering from respiratory diseases,&#8221; concluded Mr.
      Raifeld.</div>
    <div><br>
    </div>
    <div>Moelis &amp; Company acted as a financial advisor and Willkie Farr Gallagher acted as a legal advisor to Innoviva.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="font-weight: bold;">About Innoviva</div>
    <div><br>
    </div>
    <div>Innoviva, Inc. (referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar ponouns), is a company with a portfolio of royalties that include
      respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>/BREO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (fluticasone furoate/ vilanterol, &#8220;FF/VI&#8221;), ANORO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>(umeclidinium bromide/ vilanterol,
      &#8220;UMEC/VI&#8221;) and TRELEGY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of&#160; RELVAR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>/BREO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
      ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and ANORO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. Innoviva is also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (&#8220;TRC&#8221;),
      relating to TRELEGY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to
      herein as the &#8220;GSK Agreements&#8221;), which have been assigned to TRC other than RELVAR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>/BREO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and ANORO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>.</div>
    <div><br>
    </div>
    <div>ANORO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, RELVAR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, BREO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, TRELEGY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> are trademarks of the GlaxoSmithKline group of companies.</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">Forward Looking Statements</div>
    <div><br>
    </div>
    <div>This press release contains certain &#8220;forward-looking&#8221; statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding,
      among other things, statements relating to goals, plans, objectives and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the
      Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;goal&#8221;, &#8220;intend&#8221;, &#8220;objective&#8221;, &#8220;opportunity&#8221;, &#8220;plan&#8221;, &#8220;potential&#8221;, &#8220;target&#8221; and similar expressions are intended to identify
      such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press
      release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking
      statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from
      respiratory products partnered with GSK; the commercialization of RELVAR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>/BREO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, ANORO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and TRELEGY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> ELLIPTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in the jurisdictions in which these products
      have been approved; the strategies, plans and objectives of Innoviva (including Innoviva&#8217;s growth strategy and corporate development initiatives beyond the existing respiratory portfolio); the timing, manner, and amount of potential capital returns
      to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and
      commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (&#8220;COVID-19&#8221;). Other risks affecting Innoviva are described under the
      headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contained in Innoviva&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Reports on Form 10-Q, which are
      on file with the Securities and Exchange Commission (&#8220;SEC&#8221;) and available on the SEC&#8217;s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed and actual results may
      differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no
      obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="font-weight: bold;">Investor &amp; Media Contacts:</div>
    <div><br>
    </div>
    <div><u>Sloane &amp; Company</u></div>
    <div><u>James Goldfarb</u></div>
    <div><u>212-486-9500</u></div>
    <div>jgoldfarb@sloanepr.com</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0E!W4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3- "T4TMBD\P
M4 .--)I#(*86YI%)$H-.J%6J0-0)H=129I:!!1113 **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DH--
M)IC2%S0#49-*IIV'8EHI!2U)(444E !2TE H$F+1110,*2@TTFFAH=2TT4ZD
M(**** "BBB@ I**:33&AU+30:=2$%%%% !1110 4444 %%%% !1110 4444
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M!132:4&@+#J***!!1110 4444 %%%% !1110 4444 %%%)0(6BDI:!A1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8M%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOK31V4%H '%,Z/4J#Y*A;B2E<ZT>B^"S^\CKW/2?^/9?I7A/@H_O$KW72?\
MCU7Z4,X,1N:.:6FFE%!S6'4444A!2'I2TAH YG7HM\;?2O*];L?G8XKV+4XM
MZFN"UNR^5CBG<[\.]#R:_BV,:RR,FNAUJ+8[5@=Z9UVN:FD-L<5Z3H=[C:,U
MYA:/L(KK-&O,2*,U+,IQT/9](FWJO-;Z]*Y#P[-O1>:ZY?NT'G5-QU%%%!F%
M%%% !24M% #"*0"GT4%7,W4VVPFO-=?O-I89KT36GVV[5X[XEN]LC#/>D=%#
M<YK59]Y;FN9F'S&M6YFWDUES"J2.QK0?8C,P%>AZ#:;MIQ7 Z6N;D5ZUX8M=
MR)Q29@T=AHMOL"\5UT7""L;3X-@'%;2\+0CDGN.S2TSO3A39#0ZBBBD(****
M "L'76VP-]*W2:YKQ')BW;Z4%1W/)?$=UB1AFN(O)=Y-;_B6X_?L,]ZY5GW&
MBQZ%)$70U(#3"*50<TCMBM!Y7(JLZX:KRK\M5Y5^:F#.M\(-B9/K7NNA2?Z,
MM>#>%6VRI]:]LT*;]PO-.QP5XG6(<U)5:!MPJS2.!B4E.I*"6A**6BF*P4M-
MIU(:"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 E%!IN:8TAU!^Z:!0?NFD(XOQ=_J'^E
M> ^(/^/MOK7O_B[_ %#_ $KP#Q#_ ,?;?6F=5$S83Q23&FQ'BDE-,[EL=#X8
M_P"/I?K7O_A?_CV7Z5\_>%S_ *2OUKZ!\+_\>R_2I./$'4CI10.E%!QB4E.I
M*!,*6DHH!$-Q]VN;U0_(U=%<_=KF=4/R-0==#<\M\4#):O/I1B0_6O0_$O):
MO/K@8D-!Z46-#4[=4&[FG@T%)DPYI&XI5H<<4B9(GT^8K<+7JWAC4=BI\U>/
MP-ME!KL-&U(QE1NJF<=2)[K8WHD YK9C.5KSWP_J'F[?FKO;5]T8/M2.*:LR
MQ11100%%%% !1110 4E+24 5;[_4-]*\9\;]7KV:^_U#?2O%_&YY>F;4MSR>
M?_7'ZU8M!\XJ"7F8_6KEHOS"E8[U+0ZC2?O+7J'AO^&O,-+X9:].\-_PT'/5
M>AZ#;_ZL?2I#4=O_ *L?2I#0<+(6%*E.(H IDD@I::*=2*0V3[AKB?$GW6KM
M9/N&N*\2?=:@VI;GE.L?ZQJY*[^]76ZQ]]JY"[/S4T>G'8@4TXFHP:4F@NX[
M=2J>:B!YJ04-"W-.UGVD<UV_AV]PR\UYRDNTUTVAW>UUYH,:D=#W+2;S,2\U
MT$,FX5YWHM_E5&:[?3Y=ZBD>?-69J44@Z4M!F%-S2FHR: ) :6HU-24 %(W2
MEI&Z4 8.J=&KSSQ#]UJ]!U4\&O/-?/#4CLHK0\JUH?O3]:R$'SUMZPO[T_6L
MA5^>FF=:1W'A0?.E>R:-_J5KQWPL/G2O8M&_U*T[D5-CIK?I5JJMOTJS2/-G
MN!I*4TE,S8M+3:6@:8M9FK'%NU:=96L'_1FI%1W/(_$\Q#OS7G]Y,2QYKM/%
M<G[QZX.8[F-4CTJ2T*VX[JE4YJ$C!J2'E\46-&3K;[STK1M=-+$?+5C3[7S,
M<5U^F:2&Q\M(QD[&9IFDD,/EKMM+T_:%XJU8Z.% .VM^UL0@'%!C[0FL+8*!
MQ6PD8 JO!'MJVO2@PD[L,<4TU(:8:5B4*M/IBT^@3"BBB@04444 %%%% #"M
M1,E3FF,*PG"Y291GCRM8EY;YSQ71R+D52FM]W:N:=,Z(3L<E-;=>*H26^#TK
MJY[3VK+N+;&>*X*L+,V4[F R8-*#BK,T>#55N*Y]A@6J]IY/F"L^M"P'[P5M
M3>HGL=KII^05J@UD:<?D%:JUZM)Z')-:DM%%%=:,@HHHI@%9FJ+N@-:=4KY=
MT1H''<\E\1VNYFXKS_4(-I/%>MZY:[MW%><:U;["W%.YZ=*6AQLH^8U-8<3B
MFSCYS3K7B4&@J>IZ5X=N=H3FO2=)N-P7FO'M&N=A7FO3- N-^WFD<E1'>PG*
M"I*AMCF,?2IJ#D"BBB@ HHHH **** (9FPM8.IW.(FY[5L7C;4-<;K-WM5AF
M@VI[GGWBR;<7YKSF4_O#7:>(Y]Q;FN(<_O#1<]*GL31#<:V=/M]TB\=ZR[1=
MSBNLTFVW,O% JCLCO?"D.W;Q7IML,1+]*X/PY!M"\5WT'^K'TH/-J.[):***
M#(*:13J0T ,ILO\ JS4F*9-_JS3*/*?' ^22O$[P?Z4WUKV[QN/D>O%+X?Z4
MWUJD=M#85#\E0/\ ZRI%/RU'UDJ4CJ/0O!0_>1U[KI/_ !ZK]*\,\%#]Y'7N
MFD_\>J_2AGGU]R\:<*,4M!SW%HHHI""DI:2@"E=)N!KD]<M_W3'%=I*N17.Z
MY#_H[<4'32G8\.\2+MD:N5!^:NO\5+ME?ZUQA/S&@]"$KER-\5MZ1/\ Z0O-
M<T'Q6KI$O^DK]:8ZBT/=/"C[HTKND^Z*\^\(/F-*] 3[HI'DU?B'T444&844
M44 %%%% "4A-+43FF-(Q-??%NWTKQ#Q1+^^;GO7L_B!_]&;Z5X9XID_?M]:#
MMH1.>+Y-12#(I$;)J1AD4T=3V+&D)FZ6O:?"D7[M*\@T:/\ TE?K7MGA./\
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M2VAY+K$)61JQ@,&NNU^VQ(W'>N6E7::95[DD+[372:'<'SUYKDT?FN@T)_\
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M0[WA>:[_ $N?>!S7CNC7N&49KTK0KO<J\T'#4B=JIXIU589,J*LB@P8M%%%
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M:]\\7?ZA_I7@7B'_ (^V^M!U43*BZ4V6GP]*2:K.JYO>%_\ CY7ZU] >%_\
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M *L5K#I7LTGH>=/<=2TE+77$S"DI:*H!*6BB@!K_ ':PM1@W@\5O'I5&YCW
MT%1W/*_$MMM1SBO)M6^6X(KV_P 5P@1/QVKQ+6UQ<M]:&=]#5&=$?FKH=,EV
MD<UST0YK4M)-I%4C6:T/3_#]SEEYKU+26S"/I7BWANXS(HSWKV/0VS OTI,X
M*IN4444C **** $;I7.ZQ+L5JZ%_NUR/B&78C4&M+XCAM=NL[AFO-]6.Z0GW
MKK-9N\R,,UQ]ZVYC2N>HEH98&&KH-&3<RU@D?-73^'DW2+3,YGH&AVOW3BO1
M=)3:BUR>AVW[M3BNUL4VJ*#AJ,T1TI:!THH, HHHH **** "HYO]6:DJ.;_5
MF@#ROQO]UZ\4O3_I3?6O:O&_W9*\4O?^/IOK31V4=A5^[4+?ZRID^[4#?ZRF
M=#/1/!1_>1U[II/_ !ZI]*\)\%?ZR.O=M(_X]4^E)G#5W-*BBBD8A1110 44
M44 )12T4 5KD?NC]*\L\8Q9#UZM./W9^E>;>*X=P:@WI/4\6O8<3-]:I'BM_
M4;?$K<=ZQ)EP:$>G%Z#8GQ(*],\'2?,E>6H<2"O1O!\N&2@PJH]OTYLP+]*T
M16'I<P,"_2MJ,Y%!PS5B2BEHH,A*#TI::YP* 2*\[84UYYXND^1Z[B\G"J>:
M\Y\5W&Y'YI'72B>3:JV;EOK5-1FIM2;-RU10G)H.S9$J0Y8<5W'A.'$B<=ZY
M>U@WD<5WGAFVVNG%,BH_=/5]%&+9?I6O69I2X@6M.@\R6X4444""BBB@ HHH
MH BG.$-<OJESM#<UTEV<1&N$UVXVEN:"X+4XSQ)/O#<UYI?#]ZQKM]9N-^[F
MN*O.7-,[((JV_P#K0/>N_P##UOOV\5P-L/WZ_6O4O"D&X)Q29I+1'=:+:[ O
M%=A$G[H"LC38-JKQ6]$OR"DCBJ/4Q=2MLQ,<=J\B\71;2]>WW\8,#<=J\=\9
MQ<O5((2/)YO]8?K5BUX<&F31XE/UIT7RFAG9#8ZK2KC:R\UZAX:FW;>:\;L)
ML2+SWKU3PG-G;S4$55H>HVYS&/I4U5K5LQ#Z59JCA84444""BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "D/0TM(>E '&>+?\ 4/\ 2O O$(_TMOK7OWBW
M_4/]*\#\0_\ 'TWUH.FD8\72DEI4Z4DE.^AT7.A\+C_25^M>_>&/^/9?I7@?
MA?\ X^5^M>^^&/\ CV7Z4CFJG4=J*.U%!SA1110 4444 07'W*YK5#^[:NDN
M/NFN9U7[C4T;TCRKQ3R7KSF;_6GZUZ+XHZM7G4_^L/UH.Q+0O:8?WRUZ=X=^
MZE>7:9_KQ7J/AS[J4K"/1M+Z"MJ1-T?X5C:7T6N@5<I0<=1VD<QJUKF-N*\N
M\0VGS-Q7M.HP!HFKS;Q#99+<4&M.H>4W,.QC5!^M=%J=L4)XKGI!AS0=*=Q8
M3AP:Z33+_P HKS7-#BI(KDHXYIBDCVCP[J'F%>:](L7W0J:\/\*7WSIDUZ_I
M5VK0+SVH.2I$WA2$TR-]PIQH1@*#2TT4Z@&5+W_4-]*\@\9]7KU^]_U#?2O'
M_&9Y>@WH[GE%U_K6^M%M]\4ET?WK?6BV^^*1Z$3JM*^\M>I>&A]VO+])'S+7
MJ/AK^&D9U]CT&W_U8^E35#;_ .K'TJ:F>8PHHHH$%%%% #9/N&N(\2?=:NVD
M^X:XGQ)]UJ#2GN>4ZO\ ZQJY.\ZFNKU?_6-7*7G4T'H1>AG9^<5Z%X+/[R.O
M/#]^O0O!7^LCI$5'H>[:/_QZK]*OS#*$51T?_CU7Z5HL,BJ.![G):O8^:&XK
MS?7]-\L,<5[1<6H=3Q7">*+ ;'P*3-Z4];'AM]'LF(JNIK:U>T99VXK'92M2
M>C'5"AN:W]%N?+=>:YS/-7[*8HPJD*4;GL&B:IPHS7?:9<>8HYKQ'1=0(D49
MKU3P_=AD7F@X*T+'9#I2U#'(& J84'*%(W2EIK_=H P=4. :\\U\Y5J] U8\
M-7GFN'AJ#KI,\RUA<RGZUB#AZZ#5A\YK 8?O*#J1W'A0Y=*]FT9?W*UXSX2_
MUB5[3HW^H6F93.BM^@JS5>#I5B@X9;BT444B0HHHH *RM8_X]FK5K*UG_CV:
M@<=SQ?Q6?WCUP,Y^8UWGBS_6/7!3?>-!Z--:"V_WJZC1C^]6N6M_O5T^C?ZY
M:0JB/7_#)^1*[1/NBN*\,?<2NU3[M,X);CJ***"0HHHH **** "BBB@ HHHH
M *2EHI- )2T44)6 ****8!1124F &JL_2K)JO/TKFJLI&+>#@USEZ<$UTMYT
M-<Q?]37DUSKI&3(<FK>G#]Z/K5-NM7M._P!8/K7-!ZG1+8[G2_\ 5BM85DZ9
M]P5K"O8H/0\^>XZBBBNU&8M%%%:""BBB@!#4$JY4U8IC#@T#1P/BR/\ =/\
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M?"__ ![+]*^?_"__ !]+]:^@/"__ ![+]*3.6L=2.E% Z44CF"BBB@ HHHH
M@G^[7.:H?W;5T=Q]RN:U0_NVI,Z**/*O%75J\ZE_UI^M>B>*.K5YW-_K#]:$
M=J6AH:8?WJUZ7X?Z+7F.FG]\*]-\/=$JA,]%TOH*Z2+[@KF]+Z+721?<%(X*
MNX^HI4RAJ6D;D4&1PGB*R\Q6XKR[5].*.QVU[CJ-IYH/%<#XATP*C';0=-*9
MX]=IL<BJXK3UB(I,1CO66M!V+8?NQ6YH=P5G'/>L!JO:=+LD!ID2/;_#NHXC
M4;NU=K:7/F <UXUH>I%=HW5Z5HEWYBKS2.2<3K%Z4&FQG*TXT&!4OC^X;Z5X
MMXWZO7LU^?W#?2O&?&W5Z;1TT5J>4/\ ZX_6M"S/S"J$W$Q^M6[-OG%"/03T
M.PTK[RUZ;X=Z+7F.DGYEKT[PY_#2,*^QWT'^K'TJ6HH/]6/I4M!YS"BBB@04
M444 -D^[7$^)#\K5VLGW#7$>)3\K4%PW/*]8/[QJY&\^\:ZO5S^\:N5N^II(
M[$45^^*]#\&']XE>=?QUZ%X+/[R.G8)['NVD?\>J5IUF:/\ \>J?2M.@X7N)
M4,BYJ4TWK3&CG]9MPT#<5Y'XDL,NQQ7MFH1;HC7GFNV&[<<5+.VA(\@N8/+)
MXK/<\UTVM6WE%N*Y<_?(H3.]/0D@X?-=+IEUL9>:YV,8YJW;W&QQS5'-51[!
MX=O,[>:]#LY]T:\]J\;\-7G*\UZAIESNC7FD<,XG2(<BE;[M10-E:E;[M!B<
M[J_W6KSK7NC5Z-JWW6KSG7^C4CJI'F6K']Z?K6=$?F%7=7/[T_6LZ)OF%,ZE
ML=[X9^^E>MZ/_JEKR+PN?G2O7M&'[I:#.:T.GMONU;JK;=*M4'!+<****"0H
MHHH *RM8_P"/9JU:R=9_X]F^E!4=SQCQ6?WCUY_<GYC7>>+#^\?ZUP,Y^8U1
MZM+X1;7[]=?HO^L6N1M?O5U>BG]ZM3(BJCU_PU]Q*[%/NUQGAK[BUV:?=I(\
MZ>XZBBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !2445#&)5:XZ59
M-5Y^E8SV''<Q+SH:YN^[UTMX.#7,7_4UYE='=11DR=:MZ;_K1]:I/UJ]IO\
MK!]:Y8K4Z9+0[O2_]6*UQ63I?^K'TK6%>O0V/+J;CJ6DHKL1D+1115@%%%%
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MM>WZ!+_HZ_2D<E6-SJ0<TZH8FR*FJCD:L%%%% @HHHH **** "BBB@ HHHH
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M:QM-EWJ*V!TIH\ZIN+11100%%%% !1110 4444 %%%% !1110 4444 %%%%
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MC>'YC77ZQ_K&KD+W[QH1VK8H#[XKT/P6/WD=>>#[XKT3P9_K(Z")['NFC_\
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M=%X87_25^M>]^&?^/=?I7@WAC_CX7ZU[SX9_X]U^E(X,0=/VHH[44'(%%%%
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MC5REV.374:M_K6KF;JI.R)F?\M*]"\%G]Y'7GS??KT#P7_K8ZHFHM#W?1_\
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MK3ZBA.4%2TSE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!2..9;HHHH,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHI* %I#]TTM(>AH XKQ?_J'^E>
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MKI4#)L!112UM%:$B4M)2TT 44450!1110 4AI:0T 1,>:5:1A3E% $@HH%%
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M^6DQ-G5>'8=BKQ7:Q_<%<[I$&P+Q72(/EIHY9[BBGBFTX4,S8M%%%(04444
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MWO7LVA1[+=1[4SFF;M%%%!D%%%% !1110 4444 %%%% !1110 4444 %%%%
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M(BXJ04 4M=<8V1FV%%%%6D(6BBBK$%%%%( HHHI@%%%% !0:** &$4H%.HH
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M"I@@%=<*>AA*8J# J04@%.K>$3)A1116P@HHHH 6BDI:I"$I:2BDF M%%%4
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M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH 0TE.I*!A2TE+0(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I#2T4 ,(I12T4QW%HHHI""BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#3,<T\TF*:&F I
MU)2TA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% #:6BBF*PM%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M(:81S3Z3%-#0"G4E+2$PHHHH **** "BBB@ HHHH **** $I*6BF*PM%%%(8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:2G4E
MF@I:**!A3=M.HH C,8Q6;>P @\5K56FCW"DRHNS.;%KB7.*U[2+ %.^S?-G%
M6HH\"E8U<QZI3PM*!3JAQU,FQH6G 44M5%$A11156 ****8!1110 4444 %)
M2TE)H HI*6AH5PI:**$,****8!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %-IU)0)A2TE+0""BBB@84444 %%%% !1110 4444 %(:6DH ;BE%
M+BBF.XM%%%(0VEHHIBL+1112&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2$4M% #-@]*4"G44 )BBEHI6 ****8!1110 4444 %%%%
M !1110 4E+10 VEHHIDI"T444B@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHI7 ****8!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4E+25+ *6DI:$ 44450!1110 4444 %%%% !1110 4444 %%%% !24M)28!2
MTE+0@"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+128"4M)2TD
M 44450!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444@"BBBF E+24M2@"BBBJ
M**** "BBB@ HHHH **** "DI:0T"84M-IU (****!A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% "44M)4@+124M- %%%%, HHHH **
M** "BBB@ I*6B@!*6DI:!(****!A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !24M%)@)2T44( HHHI@%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
